Dr. James Stevenson Joins MedAware as Strategic Advisor to Advance the Utilization of AI within Health System Pharmacy Practice
[Boston, MA 7/15/24] – MedAware (www.medaware.com), a leading developer of AI-based medication safety solutions, proudly announces that Dr. James Stevenson, PharmD, FASHP, has joined the company as a Strategic Advisor.
Dr. Stevenson, Emeritus Professor of Pharmacy at the University of Michigan College of Pharmacy, brings a wealth of experience and expertise to his new role at MedAware. Prior to joining MedAware, Dr. Stevenson served as the VP and Chief Clinical Officer for Omnicell, Inc., where he spearheaded the company’s vision of Autonomous Pharmacy. His extensive leadership experience includes roles as Director of Pharmacy/Chief Pharmacy Officer at West Virginia University Hospitals, the Detroit Medical Center, and the University of Michigan Health System.
Commenting on the potential for MedAware to transform current pharmacy practices, Dr. Stevenson noted, “Health system pharmacists today rely on processes that leverage disjointed and fragmented technology. There’s increasing pressure on pharmacists’ time and an exponential growth in information, which means the need for tools that enable safe, clinician-assisted decision-making will only grow. I choose to work with innovative disruptors, like MedAware, to continue elevating the practice of pharmacy by using data to direct pharmacists’ attention to situations where there is the greatest need. When we’re successful at incorporating novel technologies into our existing pharmacy workflows, pharmacists can do more, more safely— ultimately improving outcomes, safety, efficiency and reducing cost.”
Dr. Stevenson’s perspective and thought leadership has been well recognized by his peers over the years. He received the Pharmacist of the Year award from the Michigan Pharmacists Association, the ASHP Award for Distinguished Leadership in Health System Pharmacy Practice, and the John W. Webb Lecture Award. He has also served on the ASHP Board of Directors and held officer positions in the Hospital Pharmacy Section of the International Pharmaceutical Federation (FIP).
MedAware’s patented AI driven software enables real-time evaluation of prescribed drugs against specific patient clinical conditions enhancing outcomes and patient safety. By incorporating a patient specific view of medication risk, the platform dramatically reduces the “alert burden” which frustrates pharmacists today. In addition, the platform continues to provide accurate and timely clinical insights beyond the point of dispensing, ensuring the patients remain safe while they take their medications.
David Franklin, CEO of MedAware, expressed excitement at Dr. Stevenson becoming a MedAware Strategic Advisor, emphasizing the value of collaboration between industry and clinical thought leaders to drive innovation in healthcare.
“We’re very fortunate to have Dr. Stevenson as a supporter and thought leader for our customers. Our collaboration is great example of how clinician-guided AI and ML can help health systems and care teams realize more from their investments in their EHR and other toolsets with the addition of a complimentary safety layer that does the heavy lifting for them. Partnering with experts like Dr. Stevenson demonstrates the value of collaboration between industry and clinical thought leaders to maintain ethical innovation with tools like clinically-conscious AI.”
By harnessing Dr. Stevenson’s insights and MedAware’s cutting-edge AI technology, the collaboration aims to drive continuous improvement in patient safety and medication management practices across healthcare organizations.
About MedAware:
MedAware’s medication safety monitoring platform lives within existing technology systems, EHRs, and devices to identify dangerous medication-related risks throughout the entire patient journey. By applying a personalized look at the appropriateness of a patient’s medication therapy at each stage of their treatment journey, MedAware’s technology can alert care teams to potential harm sooner than traditional tools—streamlining existing workflows, saving clinical time, and enabling intervention before harm occurs.
For media inquiries or further information, please contact:
Diane Smith
Chief Commercial Officer, MedAware
Email: [email protected]